New RSV Vaccines Show High Efficacy in Older Adults, Study Finds
New respiratory syncytial virus (RSV) vaccines, available in the United States, have proven to be highly effective in adults aged 60 and older. A recent large-scale study involving 14.8 million Medicare enrollees found that these vaccines reduce the likelihood of…
Baltimore, MD, September 21, 2026 — New vaccines targeting respiratory syncytial virus (RSV) have demonstrated significant effectiveness in protecting adults aged 60 and older, according to recent findings. These vaccines are now available in the United States and are aimed at reducing the incidence of severe illness from the virus in this demographic.
A comprehensive, large-scale study examined the impact of these new vaccines on a substantial population. The research involved approximately 14.8 million individuals enrolled in Medicare. The data collected indicated that the RSV vaccines are associated with a substantial decrease in the risk of adverse health outcomes.
Specifically, the study found that vaccination reduced the likelihood of hospitalization due to RSV by around 80%. Furthermore, the vaccines also showed a comparable efficacy in reducing the risk of death related to RSV infections. These findings suggest a significant public health benefit for the elderly population, who are more vulnerable to complications from RSV.
The specific manufacturers of the vaccines were not detailed in the summary information provided. Similarly, the exact timeline of the study, such as when the data was collected or published, was not specified. However, the availability of these vaccines in the U.S. signifies a new preventive measure against a virus that can cause serious respiratory illness.
Story summarized from the original created by Veronique Greenwood on time.com, see more information here.
Media gallery
